FR3063903B1 - Nouveaux composes, compositions et methodes pour le traitement de la resistance a l’insuline - Google Patents

Nouveaux composes, compositions et methodes pour le traitement de la resistance a l’insuline Download PDF

Info

Publication number
FR3063903B1
FR3063903B1 FR1752287A FR1752287A FR3063903B1 FR 3063903 B1 FR3063903 B1 FR 3063903B1 FR 1752287 A FR1752287 A FR 1752287A FR 1752287 A FR1752287 A FR 1752287A FR 3063903 B1 FR3063903 B1 FR 3063903B1
Authority
FR
France
Prior art keywords
insulin resistance
compositions
methods
novel compounds
treating insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1752287A
Other languages
English (en)
Other versions
FR3063903A1 (fr
Inventor
Maria MITEVA
Bruno Villoutreix
David J. Aitken
Anne-Francoise Burnol
Anais GONDOIN
Tarik ISSAD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris 5 Rene Descartes
Universite Paris Diderot Paris 7
Universite Paris Sud Paris 11
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris 5 Rene Descartes
Universite Paris Diderot Paris 7
Universite Paris Sud Paris 11
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris 5 Rene Descartes, Universite Paris Diderot Paris 7, Universite Paris Sud Paris 11 filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR1752287A priority Critical patent/FR3063903B1/fr
Priority to US16/496,111 priority patent/US11020378B2/en
Priority to PCT/EP2018/056931 priority patent/WO2018172306A1/fr
Priority to EP18710891.5A priority patent/EP3600296A1/fr
Publication of FR3063903A1 publication Critical patent/FR3063903A1/fr
Application granted granted Critical
Publication of FR3063903B1 publication Critical patent/FR3063903B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur un composé inhibiteur de l'interaction entre une protéine Grb14 et un récepteur de l'insuline de formule (I) ou de formule (II), leurs sels, solvates et/ou diastéréoisomères, pour une utilisation à des fins thérapeutiques, en particulier pour le traitement de l'insulinorésistance, et des compositions pharmaceutiques contenant de tels composés.
FR1752287A 2017-03-20 2017-03-20 Nouveaux composes, compositions et methodes pour le traitement de la resistance a l’insuline Expired - Fee Related FR3063903B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR1752287A FR3063903B1 (fr) 2017-03-20 2017-03-20 Nouveaux composes, compositions et methodes pour le traitement de la resistance a l’insuline
US16/496,111 US11020378B2 (en) 2017-03-20 2018-03-20 Compounds, compositions and methods for treating insulin resistance
PCT/EP2018/056931 WO2018172306A1 (fr) 2017-03-20 2018-03-20 Nouveaux composes, compositions et methodes pour le traitement de la resistance a l'insuline
EP18710891.5A EP3600296A1 (fr) 2017-03-20 2018-03-20 Nouveaux composes, compositions et methodes pour le traitement de la resistance a l'insuline

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1752287 2017-03-20
FR1752287A FR3063903B1 (fr) 2017-03-20 2017-03-20 Nouveaux composes, compositions et methodes pour le traitement de la resistance a l’insuline

Publications (2)

Publication Number Publication Date
FR3063903A1 FR3063903A1 (fr) 2018-09-21
FR3063903B1 true FR3063903B1 (fr) 2019-04-12

Family

ID=59153044

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1752287A Expired - Fee Related FR3063903B1 (fr) 2017-03-20 2017-03-20 Nouveaux composes, compositions et methodes pour le traitement de la resistance a l’insuline

Country Status (4)

Country Link
US (1) US11020378B2 (fr)
EP (1) EP3600296A1 (fr)
FR (1) FR3063903B1 (fr)
WO (1) WO2018172306A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1145822A (en) 1965-03-10 1969-03-19 May & Baker Ltd Thiazole derivatives
FR2790956B1 (fr) 1999-03-15 2003-05-23 Centre Nat Rech Scient UTILISATION DE LA PROTEINE Grb14 ET DES PROTEINES ADAPTATRICES HOMOLOGUES COMME OUTIL DE CRIBLAGE DE MOLECULES DESTINEES AU TRAITEMENT DES MALADIES LIEES A L'INSULINE
KR101411838B1 (ko) * 2011-02-09 2014-06-27 부산대학교 산학협력단 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도
WO2017205765A1 (fr) * 2016-05-27 2017-11-30 Yale University Compositions et méthodes pour l'inhibition de ptpn22

Also Published As

Publication number Publication date
FR3063903A1 (fr) 2018-09-21
US20200030297A1 (en) 2020-01-30
EP3600296A1 (fr) 2020-02-05
WO2018172306A1 (fr) 2018-09-27
US11020378B2 (en) 2021-06-01

Similar Documents

Publication Publication Date Title
MA48772B1 (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA55821B1 (fr) Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression
MA45020B1 (fr) Dérivés sulfonamides aromatiques
MA42109A (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
MA45153B1 (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
PE20180022A1 (es) Derivados de 4-metoxi-pirrol novedosos o sales de los mismos y composicion farmaceutica que comprende los mismos
MA40523B1 (fr) 2-(morpholin-4-yl)-1,7-naphthyridines
MA39554B1 (fr) Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock
MA39792B1 (fr) Composés bicycliques en tant qu'inhibiteurs de production d'autotaxine (atx) et d'acide lysophosphatidique (lpa)
TN2018000119A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
MA30405B1 (fr) Derives de 4-benzylphtalazinone substitues en 2 en tant qu'antagonistes des histamines hl et h3
TN2009000033A1 (fr) Derives de pyrazole servant d'inhibiteurs du cytochrome p450
MA29160B1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
MA43468A1 (fr) Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2
MA34067B1 (fr) Composés à base de complexes de fe(iii) pour le traitement et la prévention des carences en fer et des anémies dues à une carence en fer
MA44037B1 (fr) Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
CY1125348T1 (el) Νεοι ανταγωνιστες υποδοχεων β2 βραδυκινινης
TN2016000040A1 (fr) Inhibiteurs de porc2 et procedes pour leur utilisation
MA39927B1 (fr) Inhibiteurs de glyt1 pour le traitement de troubles hématologiques
MA41633B1 (fr) Composés amide en tant qu'agonistes du récepteur 5-ht4
MA39443A1 (fr) Nouvelle formulation de méloxicam
MA43913A (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA38358A1 (fr) Formulations de composés organiques
MA53927A (fr) Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20180921

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

ST Notification of lapse

Effective date: 20221105